Goldline Pharmaceutical Launches Initial Public Offering: Investors Should Verify GMP Compliance and Subscription Status

Goldline Pharmaceutical IPO Sees Strong Investor Sentiment on First Day

The initial public offering (IPO) of Goldline Pharmaceutical opened for subscription on May 12, 2026, and will close on Thursday, May 14. The company has set a price band of ₹41-43 per share for the SME IPO, aiming to raise ₹11.61 crore through the issue of 0.27 crore fresh shares.

The basis of allotment for the IPO is expected to be finalized on May 15, 2026. Investors who receive shares are expected to see them credited to their demat accounts by May 18, while applicants who do not receive allotment may get their refunds initiated on the same day. The company is tentatively scheduled to debut on the BSE SME platform on May 19.

The investor sentiment toward the IPO is strong, as the SME IPO's grey market premium (GMP) is ₹17 on May 12. This suggests that the stock was likely to debut at ₹60, a premium of 39.53% from the IPO price. The grey market premium indicates investors' readiness to pay more than the issue price.

Read also: SMR Jewels IPO Successfully Lists with Institutional Support

IPO Subscription Status

The subscription for this SME IPO will start at 10:00 am.

Utilization of Funds

According to the company, the funds raised through the public issue will primarily be utilized to reduce existing debt obligations, including unsecured borrowings, term loans, and working capital liabilities. A part of the proceeds will also be used for general corporate purposes, with such utilization capped at either 15% of the gross proceeds or ₹1,000 lakh, whichever is lower.

Read also: Zepto Nears $1 Billion Quarterly Net Order Value Milestone Before IPO

Investor Details

Investors can bid for a minimum of 3,000 shares in one lot. At the upper end of the price band, retail investors will need to invest a minimum of ₹2.58 lakh for 6,000 shares.

Ahead of the IPO opening, Goldline Pharmaceutical raised ₹3.15 crore from anchor investors. The anchor investor bidding process was conducted on May 11, 2026.

Issue Details

About Goldline Pharmaceutical

Goldline Pharmaceutical sells its products under the in-house "Goldline" brand and operates across five different pharmaceutical categories. The company follows an asset-light business strategy, outsourcing manufacturing to third-party partners instead of running its own production facilities. The company currently works with 15 contract manufacturers that produce medicines and healthcare products.

The company's operations are heavily dependent on external vendors for production and supply management. Distribution of products is handled through a network of eight distributors, with the company generally offering a credit period of up to 60 days. Goldline Pharmaceutical's business remains largely concentrated in western and central India, with Maharashtra and Madhya Pradesh together contributing more than 70% of its overall revenue.

Financial Performance

The company has posted steady growth in revenue over the last few years. Revenue from operations increased from ₹19.85 crore in FY2023 to ₹23.57 crore in FY2024, before rising further to ₹28.06 crore in FY2025. For the nine months ended December 31, 2025, the company reported revenue of ₹21.41 crore.

The company also witnessed a strong improvement in profitability during the period under review. Its profit after tax (PAT) margin expanded sharply from 1.31% in FY2023 to 10.09% in FY2025.